Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrotic Syndrome | 6 | 2023 | 22 | 2.670 |
Why?
|
| Podocytes | 7 | 2023 | 37 | 2.400 |
Why?
|
| Kidney Glomerulus | 8 | 2016 | 39 | 1.790 |
Why?
|
| Common Cold | 2 | 2023 | 5 | 1.640 |
Why?
|
| Proteinuria | 7 | 2023 | 48 | 1.620 |
Why?
|
| Angiopoietins | 7 | 2016 | 15 | 1.540 |
Why?
|
| Transcription Factors | 5 | 2023 | 149 | 1.480 |
Why?
|
| Kidney | 16 | 2012 | 139 | 1.330 |
Why?
|
| Homeodomain Proteins | 4 | 2023 | 55 | 1.280 |
Why?
|
| Nephrosis, Lipoid | 2 | 2023 | 11 | 1.180 |
Why?
|
| Animals | 28 | 2023 | 3238 | 1.060 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2019 | 30 | 0.970 |
Why?
|
| Mice | 18 | 2023 | 1224 | 0.870 |
Why?
|
| Hypertriglyceridemia | 2 | 2014 | 20 | 0.850 |
Why?
|
| Kidney Diseases | 5 | 2014 | 69 | 0.830 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2012 | 7 | 0.720 |
Why?
|
| Disease Models, Animal | 4 | 2011 | 512 | 0.700 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 36 | 0.480 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 229 | 0.470 |
Why?
|
| Proteins | 3 | 2003 | 52 | 0.450 |
Why?
|
| Humans | 22 | 2023 | 22592 | 0.450 |
Why?
|
| Rats | 7 | 2013 | 625 | 0.440 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 17 | 0.430 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 13 | 0.420 |
Why?
|
| Membrane Proteins | 4 | 2012 | 151 | 0.420 |
Why?
|
| Telomerase | 1 | 2012 | 8 | 0.370 |
Why?
|
| Wnt Signaling Pathway | 1 | 2012 | 29 | 0.360 |
Why?
|
| Diabetic Nephropathies | 6 | 2008 | 17 | 0.290 |
Why?
|
| Albuminuria | 2 | 2023 | 7 | 0.290 |
Why?
|
| Chimera | 1 | 2007 | 3 | 0.270 |
Why?
|
| Animals, Genetically Modified | 1 | 2007 | 17 | 0.270 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 96 | 0.260 |
Why?
|
| Fetal Diseases | 1 | 2003 | 1 | 0.210 |
Why?
|
| Glucose | 5 | 2008 | 42 | 0.210 |
Why?
|
| Glomerular Basement Membrane | 1 | 2023 | 2 | 0.210 |
Why?
|
| Recurrence | 1 | 2023 | 270 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 165 | 0.190 |
Why?
|
| Rats, Transgenic | 2 | 2011 | 17 | 0.180 |
Why?
|
| Recombinant Proteins | 3 | 2014 | 165 | 0.170 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2005 | 34 | 0.160 |
Why?
|
| Kidney Tubules | 3 | 2012 | 6 | 0.160 |
Why?
|
| Genes, Homeobox | 1 | 2019 | 4 | 0.160 |
Why?
|
| Zinc Fingers | 1 | 2019 | 10 | 0.160 |
Why?
|
| RNA, Messenger | 6 | 2012 | 280 | 0.150 |
Why?
|
| Glomerulonephritis | 2 | 2010 | 14 | 0.140 |
Why?
|
| Molecular Sequence Data | 4 | 2006 | 186 | 0.140 |
Why?
|
| rap GTP-Binding Proteins | 3 | 2008 | 3 | 0.130 |
Why?
|
| Mice, Knockout | 2 | 2010 | 277 | 0.130 |
Why?
|
| Oxidoreductases | 2 | 2005 | 9 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2006 | 312 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 31 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 2 | 2007 | 33 | 0.120 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2014 | 3 | 0.110 |
Why?
|
| Pregnancy | 6 | 2005 | 308 | 0.110 |
Why?
|
| Drug Design | 1 | 2014 | 21 | 0.110 |
Why?
|
| Autoantibodies | 2 | 2014 | 60 | 0.110 |
Why?
|
| Receptors, Vitronectin | 1 | 2013 | 5 | 0.110 |
Why?
|
| Rats, Zucker | 1 | 2013 | 7 | 0.110 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2013 | 5 | 0.110 |
Why?
|
| Serum Albumin | 1 | 2013 | 20 | 0.110 |
Why?
|
| Cadherins | 2 | 2003 | 30 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2013 | 72 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2003 | 333 | 0.100 |
Why?
|
| Lipoprotein Lipase | 1 | 2012 | 1 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 431 | 0.090 |
Why?
|
| Triglycerides | 1 | 2012 | 53 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 34 | 0.090 |
Why?
|
| Cisplatin | 1 | 2012 | 60 | 0.090 |
Why?
|
| DNA Primers | 3 | 2006 | 50 | 0.090 |
Why?
|
| Prednisone | 1 | 2011 | 64 | 0.090 |
Why?
|
| Blotting, Western | 3 | 2012 | 130 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2005 | 130 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2011 | 58 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 323 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2008 | 19 | 0.090 |
Why?
|
| Focal Infection | 1 | 2010 | 1 | 0.080 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2010 | 8 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 196 | 0.080 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2010 | 20 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 175 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2006 | 8 | 0.080 |
Why?
|
| HIV-1 | 1 | 2011 | 202 | 0.080 |
Why?
|
| Mitochondria | 1 | 2008 | 54 | 0.070 |
Why?
|
| Hyperglycemia | 2 | 2005 | 26 | 0.070 |
Why?
|
| Mice, Inbred ICR | 5 | 2008 | 11 | 0.070 |
Why?
|
| Pregnancy in Diabetics | 2 | 2005 | 4 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 51 | 0.070 |
Why?
|
| Male | 7 | 2012 | 12260 | 0.070 |
Why?
|
| Proteoglycans | 1 | 2007 | 119 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2005 | 81 | 0.070 |
Why?
|
| Cathepsin L | 1 | 2006 | 2 | 0.060 |
Why?
|
| Cathepsin B | 1 | 2006 | 3 | 0.060 |
Why?
|
| Cathepsins | 1 | 2006 | 4 | 0.060 |
Why?
|
| Cysteine Endopeptidases | 1 | 2006 | 11 | 0.060 |
Why?
|
| Protein Kinase C | 2 | 2008 | 47 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2005 | 99 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2006 | 33 | 0.060 |
Why?
|
| HIV Infections | 1 | 2011 | 421 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 2003 | 23 | 0.060 |
Why?
|
| Young Adult | 1 | 2011 | 1607 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2003 | 68 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 148 | 0.060 |
Why?
|
| Inositol Oxygenase | 1 | 2005 | 1 | 0.060 |
Why?
|
| Water-Electrolyte Balance | 1 | 2005 | 4 | 0.060 |
Why?
|
| Amyloidosis | 1 | 2005 | 12 | 0.060 |
Why?
|
| Aldehyde Reductase | 2 | 2002 | 2 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 46 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 17 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2011 | 2915 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 34 | 0.050 |
Why?
|
| Pregnancy, Animal | 1 | 2003 | 1 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 8 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2003 | 9 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2003 | 15 | 0.050 |
Why?
|
| Congenital Abnormalities | 1 | 2003 | 6 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 48 | 0.050 |
Why?
|
| Rodentia | 1 | 2003 | 6 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2003 | 16 | 0.050 |
Why?
|
| Arachidonic Acid | 1 | 2003 | 13 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 147 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 45 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2003 | 9 | 0.050 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2003 | 10 | 0.050 |
Why?
|
| Densitometry | 1 | 2003 | 8 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 26 | 0.050 |
Why?
|
| Dimerization | 1 | 2003 | 19 | 0.050 |
Why?
|
| Protein Binding | 1 | 2003 | 114 | 0.050 |
Why?
|
| Forecasting | 1 | 2003 | 77 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2003 | 23 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2003 | 33 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2003 | 30 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 101 | 0.050 |
Why?
|
| Animals, Newborn | 4 | 2005 | 41 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 6 | 0.050 |
Why?
|
| Fibronectins | 1 | 2002 | 17 | 0.050 |
Why?
|
| Mesoderm | 1 | 2002 | 18 | 0.050 |
Why?
|
| Nephrons | 1 | 2002 | 6 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2002 | 38 | 0.050 |
Why?
|
| Female | 7 | 2005 | 12734 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2003 | 537 | 0.040 |
Why?
|
| Apoptosis | 3 | 2008 | 195 | 0.040 |
Why?
|
| Time Factors | 1 | 2003 | 1247 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2012 | 467 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2008 | 15 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 2005 | 20 | 0.030 |
Why?
|
| Transfection | 2 | 2005 | 119 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 45 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2014 | 24 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2014 | 51 | 0.030 |
Why?
|
| Receptors, Lipoprotein | 1 | 2012 | 1 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2012 | 4 | 0.020 |
Why?
|
| Azo Compounds | 1 | 2012 | 3 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2012 | 2 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 24 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2012 | 14 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2012 | 8 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 2002 | 47 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 129 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 125 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 174 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 136 | 0.020 |
Why?
|
| Silicon Dioxide | 1 | 2010 | 1 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 15 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 7 | 0.020 |
Why?
|
| Vasculitis | 1 | 2010 | 26 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 98 | 0.020 |
Why?
|
| Sepsis | 1 | 2010 | 77 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 11 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 11 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 18 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 9 | 0.020 |
Why?
|
| Glycation End Products, Advanced | 1 | 2008 | 6 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 250 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 16 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 110 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2008 | 103 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 80 | 0.020 |
Why?
|
| Hypertension | 1 | 2008 | 160 | 0.020 |
Why?
|
| Sorbitol | 1 | 2005 | 1 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 12 | 0.020 |
Why?
|
| Inositol | 1 | 2005 | 5 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2005 | 22 | 0.020 |
Why?
|
| Response Elements | 1 | 2005 | 13 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 517 | 0.020 |
Why?
|
| Luciferases | 1 | 2005 | 25 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2005 | 24 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 40 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 393 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 60 | 0.010 |
Why?
|
| Embryonic Development | 1 | 2005 | 7 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 43 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 188 | 0.010 |
Why?
|
| Mammals | 1 | 2004 | 19 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2002 | 4 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2002 | 31 | 0.010 |
Why?
|
| Streptozocin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2005 | 249 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 4 | 0.010 |
Why?
|
| Wheat Germ Agglutinins | 1 | 2002 | 1 | 0.010 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2002 | 2 | 0.010 |
Why?
|
| Autoradiography | 1 | 2002 | 5 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 100 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 95 | 0.010 |
Why?
|
| Aldo-Keto Reductases | 1 | 2002 | 1 | 0.010 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2002 | 1 | 0.010 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2002 | 1 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 84 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 113 | 0.010 |
Why?
|
| Gestational Age | 1 | 2002 | 73 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2002 | 29 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 87 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2002 | 127 | 0.010 |
Why?
|
| Adult | 1 | 2010 | 6826 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 7800 | 0.010 |
Why?
|